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BACKGROUND
Chronic subdural hematoma is a common neurologic disorder that is especially 
prevalent among older people. The effect of dexamethasone on outcomes in patients 
with chronic subdural hematoma has not been well studied.
METHODS
We conducted a multicenter, randomized trial in the United Kingdom that enrolled 
adult patients with symptomatic chronic subdural hematoma. The patients were 
assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, 
starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the 
hematoma was made by the treating clinician. The primary outcome was a score of 
0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months 
after randomization; scores range from 0 (no symptoms) to 6 (death).
RESULTS
From August 2015 through November 2019, a total of 748 patients were included 
in the trial after randomization — 375 were assigned to the dexamethasone group 
and 373 to the placebo group. The mean age of the patients was 74 years, and 94% 
underwent surgery to evacuate their hematomas during the index admission; 60% in 
both groups had a score of 1 to 3 on the modified Rankin scale at admission. In a 
modified intention-to-treat analysis that excluded the patients who withdrew con-
sent for participation in the trial or who were lost to follow-up, leaving a total of 
680 patients, a favorable outcome was reported in 286 of 341 patients (83.9%) in 
the dexamethasone group and in 306 of 339 patients (90.3%) in the placebo group 
(difference, −6.4 percentage points [95% confidence interval, −11.4 to −1.4] in 
favor of the placebo group; P = 0.01). Among the patients with available data, repeat 
surgery for recurrence of the hematoma was performed in 6 of 349 patients (1.7%) 
in the dexamethasone group and in 25 of 350 patients (7.1%) in the placebo group. 
More adverse events occurred in the dexamethasone group than in the placebo group.
CONCLUSIONS
Among adults with symptomatic chronic subdural hematoma, most of whom had 
undergone surgery to remove their hematomas during the index admission, treat-
ment with dexamethasone resulted in fewer favorable outcomes and more adverse 
events than placebo at 6 months, but fewer repeat operations were performed in the 
dexamethasone group. (Funded by the National Institute for Health Research Health 
Technology Assessment Programme; Dex-CSDH ISRCTN number, ISRCTN80782810.)
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Chronic subdural hematoma is a common neurologic disorder that affects mainly older people.1 The disorder is char-
acterized by a collection of blood and blood-
breakdown products in the intracranial subdural 
space that liquefies over time. The inciting event 
is often minor head trauma, and subsequent 
inflammation may play a role in the pathogene-
sis.2 The time of onset of chronic subdural hema-
toma is often not known. The incidence of 
chronic subdural hematoma is increasing owing 
to an aging population and the use of antico-
agulant and antiplatelet medications.3 Chronic 
subdural hematoma evacuation has been pro-
jected to become the most common cranial 
neurosurgical operation among adults by the 
year 2030 in the United States.4
Patients with chronic subdural hematoma 
often present with cognitive impairment, gait 
disturbance, limb weakness, or headache, and 
the diagnosis is made on the basis of cranial 
imaging.5 Surgical evacuation of the subdural col-
lection remains the main treatment approach for 
symptomatic patients; however, the hematoma re-
curs in 10 to 20% of surgically treated patients.1,6
Glucocorticoids have been used to treat 
chronic subdural hematoma.7 Systematic reviews 
have concluded that glucocorticoids may be safe 
and effective when used in addition to surgery, 
with the aim of reducing the risk of recurrence, 
or as stand-alone therapy, with the aim of avoid-
ing surgery.8,9 However, there is limited evidence 
from multicenter, randomized trials to assess 
the effects of glucocorticoids on outcomes. We 
conducted a multicenter, randomized, placebo-
controlled trial to assess the effect of dexameth-
asone on outcomes in patients with symptom-
atic chronic subdural hematoma.
Me thods
Trial Design and Oversight
The Dexamethasone for Adult Patients with a 
Symptomatic Chronic Subdural Haematoma 
(Dex-CSDH) trial was a multicenter, randomized 
trial that was conducted in the United Kingdom. 
The trial compared a tapering 2-week course of 
dexamethasone with matching placebo in pa-
tients with symptomatic chronic subdural hema-
toma.10 Ethical approval in the United Kingdom 
was obtained from the North-West Haydock 
Research and Ethics Committee in 2015. An in-
ternal pilot randomized trial, which enrolled 
100 patients at seven trial sites, confirmed the 
operational feasibility of the overall trial.11 As pre-
specified, the pilot phase did not aim to assess 
efficacy or reestimate the sample size, and these 
patients were included in the final analysis.
When possible, written informed consent was 
obtained from the patients or from their legal 
representative if they lacked the capacity to pro-
vide consent. If a patient was unable to provide 
consent and lacked a legal representative, agree-
ment by an independent health care professional 
was necessary for enrollment. An independent 
trial steering committee and an independent data 
monitoring and ethics committee reviewed the 
trial every 6 to 12 months to assess conduct, 
progress, and safety.
The trial protocol was designed by neurosur-
geons, neurologists, stroke physicians, and geria-
tricians from several hospitals and universities 
in the United Kingdom, with methodologic input 
from members of the Cambridge Clinical Trials 
Unit. Details of the protocol have been pub-
lished previously10 and are available with the full 
text of this article at NEJM.org. The investigators 
vouch for the completeness and accuracy of the 
data and analyses, for the complete reporting of 
adverse events, and for the fidelity of the trial to 
the protocol and statistical analysis plan (avail-
able with the protocol). The analysis was con-
ducted by two authors from the Cambridge 
Clinical Trials Unit who are statisticians. The 
first draft of the manuscript was written by the 
first two authors and the last author and was 
revised by all the authors, who collectively 
agreed to submit the manuscript for publication.
Patients
Patients were eligible for enrollment if they were 
18 years or age and older and were admitted to 
a participating neurosurgical unit with symp-
tomatic chronic subdural hematoma that had 
been confirmed on cranial imaging. Trial sites 
were hospitals in the United Kingdom that pro-
vide emergency neurosurgical services 24 hours 
per day (Section S1 in the Supplementary Ap-
pendix, available at NEJM.org). A chronic sub-
dural hematoma was defined pragmatically as a 
predominantly hypodense or isodense (relative 
to the brain) crescentic collection along the ce-
rebral convexity on computed tomography (CT) 
of the head. Symptoms that were attributable to 
a chronic subdural hematoma and met trial in-
clusion criteria included headache, gait distur-
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bance, confusion or cognitive decline, limb weak-
ness, speech disturbance, drowsiness or decreased 
consciousness, and seizures. Patients with mild 
or severe symptoms were enrolled; none of the 
enrolled patients were asymptomatic.
Patients were excluded if they had conditions 
for which glucocorticoids are contraindicated 
(e.g., active systemic infection, recent peptic ul-
ceration or gastrointestinal bleeding), were re-
ceiving (or had been receiving within 1 month 
before screening) oral or intravenous glucocorti-
coids on a regular basis, were previously en-
rolled in this trial for a separate chronic subdu-
ral hematoma episode, had a cerebrospinal fluid 
shunt, had severe lactose intolerance or a known 
hypersensitivity to dexamethasone or other ex-
cipient, had a history of psychotic disorders, or 
were unwilling to take products containing gela-
tin. Patients were not eligible for randomization 
if they were not able to receive the first dose of 
the trial drug or placebo within 72 hours after 
admission to the neurosurgical unit. Patients 
with an acute hematoma, as indicated by a pre-
dominantly hyperdense (relative to the brain) 
subdural collection on a CT scan, were not eli-
gible for randomization.
Randomization
Patients were treated in neurosurgical units ac-
cording to standard practice. In the United 
Kingdom, standard practice typically includes 
burr hole evacuation of the hematoma with the 
use of a subdural drain.5 The decision to per-
form surgical evacuation of the subdural collec-
tion or conservative monitoring was made by the 
clinical team in conjunction with the patient. 
Enrollment took place irrespective of the deci-
sion to operate and the timing of the surgical 
intervention.
Eligible patients were randomly assigned in a 
1:1 ratio to receive a tapering 2-week course of 
oral dexamethasone (8 mg twice daily on days 1 
to 3, then 6 mg twice daily on days 4 to 6, then 
4 mg twice daily on days 7 to 9, then 2 mg twice 
daily on days 10 to 12, and then 2 mg once 
daily on days 13 and 14) or matching placebo. If 
oral administration was not possible, the trial 
agent was administered in a nasogastric tube. 
Patients could complete the tapering course at 
home if they were discharged. Adherence was 
assessed by reviewing medication records and 
patient diaries if the medication was taken at 
home. Randomization was performed with the 
use of permuted blocks (random block sizes of 
two or four), with stratification according to 
trial site. An interactive Web-based response 
system was used for allocating treatment packs 
of 62 dexamethasone tablets (2 mg) or 62 pla-
cebo capsules, both overencapsulated to look 
identical. The assigned trial drug or placebo was 
administered as part of the routine drug round 
by unit nurses.
Outcomes
In keeping with previous studies of chronic sub-
dural hematomas,5,12 the primary outcome was a 
score of 0 to 3 on the modified Rankin scale at 
6 months after randomization. The modified 
Rankin scale is an ordinal outcome scale of dis-
ability or dependence with respect to activities of 
daily living and was originally designed for use 
in patients with stroke but is used in patients 
with other disorders, including chronic subdural 
hematoma.13,14 The scale has seven categories: 
no symptoms (0), no clinically significant dis-
ability despite symptoms (1), slight disability (2), 
moderate disability (3), moderately severe dis-
ability (4), severe disability (5), and death (6); in 
this trial, a score of 0 to 3 was used to represent 
a favorable outcome.
Our hypothesis was that dexamethasone would 
improve the 6-month functional outcome in pa-
tients with symptomatic chronic subdural hema-
toma by reducing the need for surgical interven-
tions and recurrence of the hematoma after 
surgery. The scores on the modified Rankin 
scale were assessed with the use of a validated 
simplified questionnaire, which was completed 
by the patients or caregivers at 3 months and 
6 months after randomization; if no response 
was received, a trial team member contacted the 
patient or caregiver by telephone to complete 
the questionnaire.15 All completed questionnaires 
were reviewed at the coordinating center by a 
clinically trained investigator, who was unaware 
of the trial-group assignments; this investigator 
calculated the modified Rankin scale score ac-
cording to a standardized algorithm (Section S3).
Secondary outcomes were the score on the 
modified Rankin scale at discharge from the 
neurosurgical unit and at 3 months after ran-
domization; mortality at 30 days and 6 months 
after randomization; the number of patients who 
underwent surgical interventions related to 
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chronic subdural hematoma during the index 
admission; the number of patients who under-
went surgical interventions related to chronic 
subdural hematoma during subsequent admis-
sions in the follow-up period; the score on the 
Glasgow Coma Scale (scores range from 3 to 15, 
with higher scores indicating better neurologic 
status) at discharge and at 6 months; the score on 
the Barthel Index at discharge and at 3 months 
and 6 months after randomization (scores range 
from 0 to 100, with higher scores indicating 
a greater ability to complete activities of daily 
living)16; EuroQol Group 5-Dimension 5-Level 
questionnaire (EQ-5D-5L) utility index score at 
discharge and at 3 months and 6 months after 
randomization (responses on the EQ-5D-5L were 
converted into a utility index score with the use 
of the cross-walk algorithm; scores range from 
−0.594 [health state worse than death] to 1 [per-
fect health state] — patients who died were 
given a score of zero)17,18; length of stay in the 
neurosurgical unit; discharge destination from 
the neurosurgical unit; length of stay in second-
ary care; and adverse events. Postoperative recur-
rence of subdural hematoma was a tertiary out-
come that was defined as a symptomatic recurrence 
leading to reoperation of a previously evacuated 
ipsilateral chronic subdural hematoma.19 Ad-
verse events of special interest included hyper-
glycemia leading to treatment or discontinuation 
of the trial regimen, new-onset diabetes, hyperos-
molar hyperglycemic state, new-onset psychosis, 
peptic ulceration or gastrointestinal bleeding, 
and other upper gastrointestinal side effects.10
Statistical Analysis
Assuming a loss to follow-up of 15%, we esti-
mated that a target sample size of 750 patients 
would provide the trial with a power of 81 to 
92% (at a two-sided significance level of 5%) to 
detect a treatment effect of 8 percentage points, 
indicating an increase in the percentage of pa-
tients with a favorable outcome from between 
80 and 85% to between 88 and 93%.10 This dif-
ference of 8 percentage points was determined 
to be a clinically relevant treatment effect on the 
basis of estimates of a favorable outcome in 80 
to 85% of patients in previous studies.12 A pre-
specified blinded interim analysis of pooled 
outcome data was performed after 450 patients 
had completed 6 months of follow-up in order to 
decide if the sample size had to be adjusted. The 
possible alternatives after the interim analysis 
were to increase the sample size (with a maxi-
mum of 1000 patients) or to stop the trial for 
futility if the revised sample size was more than 
1000 patients. Because the trial could only be 
stopped for futility, we did not adjust the confi-
dence interval and P value at the end of the trial 
to account for the interim analysis. The indepen-
dent data monitoring and ethics committee rec-
ommended that recruitment should continue to 
the original target sample size of 750 patients. 
The analysis was conducted according to a sta-
tistical analysis plan,19 which was agreed on 
without reference to the unblinded data (see the 
protocol). No alpha-spending adjustment was 
required as a result of the 100-patient pilot trial, 
because this pilot phase was designed solely to 
determine the operational feasibility of continu-
ing the trial.
Outcome analyses were performed in the 
modified intention-to-treat population, which in-
cluded all randomly assigned patients except 
those who withdrew consent for participation in 
the trial and those lost to follow-up. Here we 
present the results of an analysis of the primary 
outcome, with a sensitivity analysis under miss-
ing-not-at-random assumptions, as described in 
Section S11.
The primary analysis estimated the absolute 
between-group difference in the percentage of 
patients who had a favorable outcome (i.e., a 
score of 0 to 3 on the modified Rankin scale 
at 6 months), under the assumption of a normal 
distribution and with the level of significance set 
at a two-sided P value of less than 0.05. As sec-
ondary analyses of the primary outcome, logistic-
regression and proportional-odds logistic-regres-
sion (using the ordinal modified Rankin scale 
score20) analyses that adjusted for the baseline 
covariates of age and Glasgow Coma Scale score 
were planned; however, the proportional-odds 
logistic-regression analysis could not be per-
formed because the proportionality assumption 
was violated. A sensitivity analysis was performed 
in the per-protocol population, which included 
all randomly assigned patients except those who 
received less than 80% of their assigned inter-
vention or received more than 8 mg of dexa-
methasone if in the placebo group (e.g., for 
postoperative nausea and vomiting). There was 
no plan for adjustment of confidence intervals 
for multiple comparisons of secondary outcomes, 
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and these outcomes are reported as point esti-
mates with confidence intervals that have not 
been adjusted for multiplicity and from which no 
clinical conclusions can be drawn.
Exploratory analyses were performed to ex-
amine the effect of interaction between treat-
ment and prespecified subgroups on the primary 
outcome. Other exploratory analyses are listed 
in Section S6. Safety data on serious adverse 
events and adverse events of special interest col-
lected in the first 30 days (Section S2) are pre-
sented as incidence rates and relative risks with 
95% confidence intervals, classified according to 
system organ class in the Medical Dictionary for 
Regulatory Activities and stratified according to 
trial group. If the outcome of an adverse event of 
special interest was considered serious, then it 
was included in the serious adverse event group. 
A health economic analysis was prespecified in 
the trial protocol but has not yet been performed.
R esult s
Patients
From August 2015 through November 2018, pa-
tients were enrolled in the trial at 23 sites in the 
United Kingdom. A total of 2203 patients were 
screened for eligibility, and 750 patients were 
randomly assigned to a trial group. Two patients 
were excluded immediately after randomization 
owing to ineligibility; neither patient had re-
ceived their assigned intervention, and no data 
were collected from these patients. Thus, 748 
patients were enrolled in the trial — 375 in the 
dexamethasone group and 373 in the placebo 
group (Fig. 1). A total of 45 patients (20 in the 
dexamethasone group and 25 in the placebo 
group) withdrew their consent to participate in 
the trial, and 23 patients were lost to final fol-
low-up (14 in the dexamethasone group and 9 in 
the placebo group). The remaining 680 patients, 
constituting the modified intention-to-treat pop-
ulation, were followed up for the primary out-
come at 6 months (341 in the dexamethasone 
group and 339 in the placebo group). With re-
spect to the primary outcome, data were missing 
for 9% of the patients (34 patients in each trial 
group). A similar amount of data were missing 
for the secondary outcomes.
The baseline characteristics were similar in 
the two trial groups, with 59.9% of the patients 
having a score of 1 to 3 on the modified Rankin 
scale and 94.3% having a score of 13 to 15 on 
the Glasgow Coma Scale at admission. Approxi-
mately 70% of the patients had a history of 
known head trauma. Fewer patients in the dexa-
methasone group than in the placebo group 
were independently mobile without any aids be-
fore they received their diagnosis of chronic 
subdural hematoma (Table 1 and Table S5). 
Atrial fibrillation was reported in 20.9% of the 
patients, and 46.6% of the patients were taking 
an antithrombotic medication at the time of di-
agnosis. The imaging characteristics of chronic 
subdural hematoma were similar in the two trial 
groups.
Among the 742 patients who could be evalu-
ated, 699 (94.2%) underwent surgical evacuation 
of the hematoma that was present during the 
initial admission, when they underwent random-
ization; surgery was performed either during the 
index admission (683 patients [342 in the dexa-
methasone group and 341 in the placebo group]) 
or during a subsequent admission (16 patients 
[5 in the dexamethasone group and 11 in the 
placebo group]). The surgical techniques used 
for evacuation of the subdural hematoma and 
adherence to the assigned regimen were similar 
in the trial groups (Table S5). Nasogastric tube 
administration of dexamethasone was reported 
in 6 of 375 patients in the dexamethasone group 
and in 4 of 373 patients in the placebo group.
Primary Outcome
In the modified intention-to-treat analysis, a fa-
vorable outcome (a score of 0 to 3 on the modi-
fied Rankin scale) was reported in 286 of 341 
patients (83.9%) in the dexamethasone group 
and in 306 of 339 patients (90.3%) in the placebo 
group at 6 months, for a between-group differ-
ence of −6.4 percentage points (95% confidence 
interval [CI], −11.4 to −1.4) in favor of the pla-
cebo group (P = 0.01) (Table 2). The ordinal out-
comes of the modified Rankin scale in each 
trial group at 6 months after randomization are 
provided in Table 2, and the dichotomous scores 
at discharge and at 3 months and 6 months after 
randomization are provided in Figure 2. After 
adjustment for prespecified covariates of age 
and Glasgow Coma Scale score at admission, the 
odds ratio for a favorable outcome with dexa-
methasone was 0.55 (95% CI, 0.33 to 0.91) in 
favor of the placebo group (P = 0.02). In the per-
protocol analysis, a favorable outcome was re-
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ported in 229 of 270 patients (84.8%) in the 
dexamethasone group and in 258 of 283 patients 
(91.2%) in the placebo group at 6 months, for a 
between-group difference of −6.4 percentage 
points (95% CI, −12.0 to −0.97) in favor of the 
placebo group (P = 0.02).
Secondary and Tertiary Outcomes
At 3 months, a favorable outcome was reported 
in 268 of 322 patients (83.2%) in the dexameth-
asone group and in 298 of 326 patients (91.4%) 
in the placebo group, for a between-group dif-
ference of −8.2 percentage points (95% CI, −13.3 
to −3.1) in favor of the placebo group. The per-
centage of patients who underwent one operation 
for their chronic subdural hematoma during the 
index admission was 91.7% in dexamethasone 
group and 89.2% in placebo group. During sub-
sequent admissions, 19 of 372 patients (5.1%) in 
the dexamethasone group and 28 of 370 patients 
(7.6%) in the placebo group underwent surgery 
related to the hematoma. Repeat surgery for re-
currence of chronic subdural hematoma was 
performed in 6 of 349 patients (1.7%) in the 
dexamethasone group and in 25 of 350 patients 
(7.1%) in the placebo group, for a between-group 
difference of 5.4 percentage points in favor of 
the dexamethasone group; 4 patients underwent 
Figure 1. Screening, Randomization, and Follow-up.
750 Were enrolled and underwent randomization
2203 Patients were assessed for eligibility
1453 Were not enrolled
328 Declined participation
291 Could not be recruited in 72 hr time window
216 Had medical contraindications
109 Were taking or had recently taken glucocorticoids
89 Had contraindications to glucocorticoids
86 Could not take medication because of problems
with swallowing or inability to adhere to the regimen
178 Were not enrolled for other reasons
156 Had no reason given
2 Were excluded immediately owing to ineligibility
375 Were assigned to dexamethasone
365 Received dexamethasone
373 Were assigned to placebo
361 Received placebo
20 Withdrew consent
9 Were lost to follow-up
322 Were evaluated at 3 months
24 Had data that were missing at 3 months
but were available at 6 months
326 Were evaluated at 3 months
24 Had data that were missing at 3 months
but were available at 6 months
22 Withdrew consent
1 Was lost to follow-up
5 Were lost to follow-up
341 Were evaluated at 6 months 339 Were evaluated at 6 months
3 Withdrew consent
8 Were lost to follow-up
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multiple operations (1 in the dexamethasone 
group and 3 in the placebo group).
Adverse events of special interest occurred in 
41 of 375 patients (10.9%) in the dexamethasone 
group and in 12 of 373 patients (3.2%) in the 
placebo group (odds ratio, 3.4 [95% CI, 1.81 to 
6.85]), and serious adverse events occurred in 
60 of 375 (16.0%) and 24 of 373 (6.4%), respec-
tively (odds ratio, 2.49 [95% CI, 1.54 to 4.15]). 
The risk of any infection was 6.4% in the dexa-
methasone group and 1.1% in the placebo 
group. Among the 699 patients who could be 
evaluated, 12 (1.7% [8 in the dexamethasone 
group and 4 in placebo group]) had a surgical 






Age — yr 74.5±11.8 74.3±11
Male sex — no./total no. (%) 268/375 (71.5) 286/373 (76.7)
Symptoms at presentation — no./total no. (%)†
Headache 211/373 (56.6) 214/373 (57.4)
Gait disturbance 171/373 (45.8) 170/373 (45.6)
Cognitive impairment 129/373 (34.6) 128/373 (34.3)
Hemiparesis 105/373 (28.2) 107/373 (28.7)
Speech disturbance 81/373 (21.7) 94/373 (25.2)
Seizure 11/373 (2.9) 10/373 (2.7)
Other 54/373 (14.5) 66/373 (17.7)
Modified Rankin scale score at admission — no./total no. (%)‡
1–3 186/310 (60.0) 182/304 (59.9)
4–5 124/310 (40.0) 122/304 (40.1)
Glasgow Coma Scale score at admission — no./total no. (%)§
13–15 350/371 (94.3) 350/371 (94.3)
9–12 15/371 (4.0) 15/371 (4.0)
3–8 6/371 (1.6) 6/371 (1.6)
Known head trauma — no./total no. (%) 253/373 (67.8) 267/373 (71.6)
Main coexisting medical conditions — no./total no. (%)
Atrial fibrillation 88/375 (23.5) 68/373 (18.2)
Diabetes 55/375 (14.7) 54/373 (14.5)
Ischemic heart disease 58/375 (15.5) 50/373 (13.4)
Previous stroke 34/375 (9.1) 39/373 (10.5)
Any antithrombotic medication — no./total no. (%) 178/370 (48.1) 166/368 (45.1)
Midline shift on admission scan — no./total no. (%)
0–5 mm 68/314 (21.7) 74/318 (23.3)
6–10 mm 126/314 (40.1) 115/318 (36.2)
>10 mm 120/314 (38.2) 129/318 (40.6)
*  Plus–minus values are means ±SD. There were no clinically significant between-group differences in these baseline 
characteristics except for mobility before chronic subdural hematoma diagnosis. Total numbers of patients that are 
less than 375 in the dexamethasone group and 373 in the placebo group indicate that data were missing for some pa-
tients. Percentages may not total 100 because of rounding. Additional baseline data are provided in Section S4 in the 
Supplementary Appendix.
†  Patients often had more than one symptom at presentation.
‡  Scores on the modified Rankin scale range from 0 (no symptoms) to 6 (death).
§  Scores on the Glasgow Coma Scale range from 3 to 15, with higher scores indicating better clinical status.
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site infection — 2 patients had a superficial 
wound infection and 10 had a subdural empy-
ema. The results for the remaining secondary 
outcomes, including mortality, EQ-5D-5L utility 
index score, length of stay, and discharge desti-
nation, are provided in Table 2 and Table S7.
The results of exploratory subgroup analyses 
are provided in Table S6. Among the 38 patients 
who received conservative management (i.e., 
those who did not undergo surgical evacuation 
of the hematoma that was evident on initial ad-
mission), a favorable outcome was reported in 
18 of 22 patients (82%) in the dexamethasone 
group and in 16 of 16 patients (100%) in the 
placebo group.
Discussion
In this trial involving patients with symptomatic 
chronic subdural hematoma, we found that the 
percentage of patients who had a favorable out-
come (defined as a score of 0 to 3 on the modi-
fied Rankin scale at 6 months) was lower among 
those who received a 14-day tapering course of 
dexamethasone than among those who received 
placebo. Surgical evacuation of the chronic sub-
dural hematoma was performed in 94% of the 
patients during the trial period, a percentage that 
is similar to that reported in a previous prospec-
tive, multicenter, observational study in the Unit-
ed Kingdom.5 At admission, 60% of the patients 
had a score of 1 to 3 on the modified Rankin 
scale, and at 6 months, 87% of the patients had a 
score of 0 to 3; these findings are also in accor-
dance with the results of prospective studies.5,12
We hypothesized that dexamethasone, as com-
pared with placebo, would improve outcomes 
in patients with symptomatic chronic subdural 
hematoma by leading to clinical improvement 
that was adequate to enable nonoperative man-
agement and by reducing the risk of recurrence 
of the hematoma in patients who had undergone 
surgery.21-24 However, contrary to our hypothesis, 
the result with respect to the primary outcome, 
a favorable outcome at 6 months, was worse in 
the dexamethasone group. Although the between-
group difference of 6.4 percentage points was 
below the 8 percentage-point difference used in 
the power calculation, this difference may be 
clinically relevant and may suggest harm associ-
ated with dexamethasone with regard to a favor-
able outcome on the modified Rankin scale. 
Because almost all the patients underwent an 
initial operation to remove the hematoma, no 
firm conclusions could be drawn regarding the 
effect of dexamethasone as a method of conser-
vative management to avoid surgery. The percent-
age of patients who underwent reoperation be-
cause of a recurrence of chronic subdural 
hematoma was 5.4 percentage points lower in 
the dexamethasone group than in the placebo 
group.
The treatment regimen consisted of a total 
124 mg of dexamethasone administered as a ta-
pering course over 14 days. The dosage and treat-
ment duration in this trial were selected on the 
basis of previous studies8 and are similar to the 
dosage and treatment duration used in other on-
going trials of glucocorticoids, although longer 
treatment durations of 3 and 8 weeks are also 
being evaluated.25 The median time to recur-
rence of chronic subdural hematoma after surgi-
cal evacuation has been 12 to 15 days in several 
studies, and this was the rationale for designing 
the trial with a 2-week treatment period with 
dexamethasone.5,12 More adverse events, such as 
hyperglycemia, new-onset diabetes, new-onset 
psychosis, and infections, were reported in the 
dexamethasone group than in the placebo group 
in our trial. It is possible that a shorter course 
with a smaller dose could reduce these risks.
A previous randomized, controlled trial that 
involved 20 patients at a single center assessed 
a 3-week course of dexamethasone at a dose of 
12 mg per day, followed by a tapering course of 
dexamethasone, as treatment for asymptomatic 
or minimally symptomatic chronic subdural hema-
toma.26 During the 6-month follow-up, surgical 
intervention in that trial had to be performed in 
4 patients, of whom 3 were in the placebo group. 
There were more serious adverse events in the 
dexamethasone group than in the placebo group. 
Our trial was larger, enrolled a different patient 
population, and had a shorter duration of treat-
ment, but we also observed that the percentage 
of patients with adverse events was higher in the 
dexamethasone group than in the placebo group.
Our trial has limitations. First, the majority 
of patients were treated surgically during their 
index admission, which limits our ability to draw 
conclusions regarding patients in whom the in-
tention is to initially manage the subdural col-
lection conservatively. The results of the explor-
atory subgroup analysis of the small number of 
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Table 2. Efficacy and Safety Outcomes.*
Variable Dexamethasone Placebo Measure of Effect†
Difference or Odds or 
Rate Ratio (95% CI) P Value
Primary outcome
Modified Rankin scale score at 6 mo — no./
total no. (%)
Dichotomous outcomes
0–3: Primary outcome 286/341 (83.9) 306/339 (90.3) Percentage-point  
difference
   −6.4 (−11.4 to −1.4) 0.01
4–6 55/341 (16.1) 33/339 (9.7)
Ordinal outcomes
0: No symptoms 163/341 (47.8) 164/339 (48.4)
1: No clinically significant disability 49/341 (14.4) 55/339 (16.2)
2: Slight disability 14/341 (4.1) 21/339 (6.2)
3: Moderate disability 60/341 (17.6) 66/339 (19.5)
4: Moderately severe disability 10/341 (2.9) 9/339 (2.7)
5: Severe disability 15/341 (4.4) 7/339 (2.1)
6: Dead 30/341 (8.8) 17/339 (5.0)
Secondary, tertiary, and safety outcomes
Modified Rankin scale score at 3 mo — no./
total no. (%)
0–3 268/322 (83.2) 298/326 (91.4) Percentage-point  
difference
   −8.2 (−13.3 to −3.1)
4–6 54/322 (16.8) 28/326 (8.6)
Modified Rankin scale score at discharge  
— no./total no. (%)
0–3 255/318 (80.2) 263/316 (83.2) Percentage-point  
difference
−3.0 (−9.1 to 3.0)
4–6 63/318 (19.8) 53/316 (16.8)
Mortality at 30 days — no./total no. (%) 8/375 (2.1) 2/373 (0.5) Odds ratio 4.08 (1.01 to 27.2)
Mortality at 6 mo — no./total no. (%) 30/341 (8.8) 17/339 (5.0) Odds ratio  1.83 (0.99 to 3.45)
One operation during index admission  
— no./total no. (%)
341/372 (91.7) 330/370 (89.2) Rate ratio‡ 0.97 (0.83 to 1.12)
Operations during subsequent admissions 
— no./total no. (%)
19/372 (5.1) 28/370 (7.6) Rate ratio‡ 0.90 (0.72 to 1.11)
Repeat surgery for recurrence of chronic sub-
dural hematoma — no./total (%)§
6/349 (1.7) 25/350 (7.1) Percentage-point  
difference
−5.4 (−8.7 to −2.5)
Mean EQ-5D-5L utility index score¶
At discharge 0.697 0.727 Difference   −0.03 (−0.07 to 0.01)
At 3 mo 0.707 0.773 Difference   −0.07 (−0.12 to −0.02)
At 6 mo 0.733 0.766 Difference   −0.03 (−0.09 to 0.02)
Adverse events of special interest up to day 30 
— no./total no. (%)‖
41/375 (10.9) 12/373 (3.2) Odds ratio 3.40 (1.81 to 6.85) <0.001
Serious adverse events up to day 30 — no./
total no. (%)‖
60/375 (16.0) 24/373 (6.4) Odds ratio 2.49 (1.54 to 4.15) <0.001
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patients who received nonoperative management, 
however, were in the same direction of effect as 
the results of the primary analysis. Second, loss 
to follow-up at 6 months was 9%. Our sample-
size calculation had allowed for up to 15% loss 
to follow-up, and the percentage was similar in 
the two trial groups. Third, owing to the charac-
teristic adverse effects of dexamethasone, the 
clinical teams and patients may have become 
aware of the trial-group assignment. Finally, 
*  Because of the lack of a prespecified plan for adjusting confidence intervals for multiple comparisons, no definite conclusions can be drawn 
from secondary outcome data in the trial. Percentages may not total 100 because of rounding.
†  Between-group differences were calculated as the value in the dexamethasone group minus the value in the placebo group, and odds ratios 
are shown for the dexamethasone group as compared with the placebo group.
‡  Data were missing for 3 patients in dexamethasone group and 3 patients in placebo group. Additional data are provided in Section S7 in the 
Supplementary Appendix. The number of operations were analyzed with the use of a Poisson regression model, which provides an estimate 
of the ratio of the mean number of operations between the trial groups; a value of less than 1 indicates fewer operations occurred in the 
dexamethasone group.
§  A total of 43 patients underwent more than one cranial surgery during the trial period. Among these 43 patients, repeat surgery was per-
formed in 31 for recurrent chronic subdural hematoma, in 10 for empyema (1 of the 10 patients who underwent repeat surgery for empy-
ema also had undergone repeat surgery for a previous recurrence of chronic subdural hematoma), in 2 for expansion of contralateral side 
chronic subdural hematoma, and in 1 for postoperative acute subdural hematoma. The time interval to the first repeat surgery for recur-
rence of chronic subdural hematoma was a mean of 18 days and a median of 14 days.
¶  The responses on the EuroQol Group 5-Dimension 5-Level questionnaire (EQ-5D-5L) were converted into a utility index score with the use 
of the cross-walk algorithm; scores range from −0.594 [health state worse than death] to 1 [perfect health state] — patients who died were 
given a score of zero. Linear regression was used to estimate the treatment effect and 95% confidence interval.
‖  Additional data on adverse events of special interest and serious adverse events are provided in Sections S8 and S9.
Table 2. (Continued.)
Figure 2. Modified Rankin Scale Score at Discharge and at 3 Months and 6 Months after Randomization.
The proportionality assumption was not upheld, and common odds ratios could not be calculated.
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follow-up imaging was not mandated as part of 
the trial, and the trial outcomes did not include 
imaging results to address the possible effect of 
dexamethasone on the size of chronic subdural 
hematomas. This was not believed to be neces-
sary in a pragmatic trial, and there is evidence 
that routine follow-up imaging after surgical 
evacuation of chronic subdural hematoma is not 
beneficial with regard to the score on the modi-
fied Rankin scale at 6 months.27
In this trial involving patients with chronic 
subdural hematoma, most of whom had under-
gone surgical evacuation during the index ad-
mission, treatment with dexamethasone resulted 
in a fewer favorable outcomes than placebo at 
6 months, but fewer repeat operations for reac-
cumulation of the subdural collection were per-
formed among the patients who received dexa-
methasone. Dexamethasone was associated with 
more adverse events than placebo.
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